MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Cytek Biosciences Inc

Închisă

SectorSănătate

5.39 -3.92

Rezumat

Modificarea prețului

24h

Curent

Minim

5.38

Maxim

5.48

Indicatori cheie

By Trading Economics

Venit

105K

-5.5M

Vânzări

6.7M

52M

EPS

-0

Marjă de profit

-10.476

Angajați

692

EBITDA

6.4M

-4.2M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+10.97% upside

Dividende

By Dow Jones

Următoarele câștiguri

26 feb. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

240M

742M

Deschiderea anterioară

9.31

Închiderea anterioară

5.39

Sentimentul știrilor

By Acuity

17%

83%

18 / 361 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Cytek Biosciences Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

16 ian. 2026, 23:29 UTC

Acțiuni populare

Stocks to Watch: Atossa Therapeutics, Union Pacific

16 ian. 2026, 22:48 UTC

Achiziții, Fuziuni, Preluări

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 ian. 2026, 22:43 UTC

Achiziții, Fuziuni, Preluări

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 ian. 2026, 22:22 UTC

Achiziții, Fuziuni, Preluări

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 ian. 2026, 21:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Tech, Media & Telecom Roundup: Market Talk

16 ian. 2026, 21:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Auto & Transport Roundup: Market Talk

16 ian. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 ian. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

16 ian. 2026, 21:48 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 ian. 2026, 21:41 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 ian. 2026, 21:38 UTC

Achiziții, Fuziuni, Preluări

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 ian. 2026, 21:30 UTC

Achiziții, Fuziuni, Preluări

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 ian. 2026, 21:30 UTC

Achiziții, Fuziuni, Preluări

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 ian. 2026, 21:30 UTC

Achiziții, Fuziuni, Preluări

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 ian. 2026, 21:30 UTC

Achiziții, Fuziuni, Preluări

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 ian. 2026, 21:30 UTC

Achiziții, Fuziuni, Preluări

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 ian. 2026, 20:44 UTC

Câștiguri

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 ian. 2026, 20:42 UTC

Market Talk

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 ian. 2026, 20:28 UTC

Market Talk

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 ian. 2026, 19:12 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 ian. 2026, 18:53 UTC

Market Talk

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 ian. 2026, 18:41 UTC

Market Talk

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 ian. 2026, 18:31 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 ian. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

16 ian. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 ian. 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

16 ian. 2026, 17:03 UTC

Market Talk

Global Equities Roundup: Market Talk

16 ian. 2026, 17:03 UTC

Market Talk

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16 ian. 2026, 16:32 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16 ian. 2026, 16:20 UTC

Market Talk

Global Equities Roundup: Market Talk

Comparație

Modificare preț

Cytek Biosciences Inc Așteptări

Obiectiv de preț

By TipRanks

10.97% sus

Prognoză pe 12 luni

Medie 6.17 USD  10.97%

Maxim 7.5 USD

Minim 5 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCytek Biosciences Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

3 ratings

2

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

3.7 / 3.8Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

18 / 361 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat